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Abstract 
The study of individuals with autosomal dominant Alzheimer’s disease affords one of the best 
opportunities to characterize the biological and cognitive changes of Alzheimer’s disease that 
occur over the course of the preclinical and symptomatic stages. Unifying the knowledge gained 
from the past three decades of research in the world’s largest single-mutation autosomal 
dominant Alzheimer’s disease kindred — a family in Antioquia, Colombia with the E280A 
mutation in the Presenilin1 gene — will provide new directions for Alzheimer’s research and a 
framework for generalizing the findings from this cohort to the more common sporadic form of 
Alzheimer’s disease. As this specific mutation is virtually 100% penetrant for the development 
of the disease by midlife, we use a previously defined median age of onset for mild cognitive 
impairment for this cohort to examine the trajectory of the biological and cognitive markers of 
the disease as a function of the carriers’ estimated years to clinical onset. Studies from this 
cohort suggest that structural and functional brain abnormalities — such as cortical thinning and 
hyperactivation in memory networks — as well as differences in biofluid and in vivo 
measurements of Alzheimer’s-related pathological proteins distinguish Presenilin1 E280A 
mutation carriers from non-carriers as early as childhood, or approximately three decades before 
the median age of onset of clinical symptoms. We conclude our review with discussion on future 
directions for Alzheimer’s disease research, with specific emphasis on ways to design studies 
that compare the generalizability of research in autosomal dominant Alzheimer’s disease to the 
larger sporadic Alzheimer’s disease population.  
 
 
Key words: autosomal dominant Alzheimer’s disease; dementia; biomarkers; cognitive markers 
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Introduction  
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that is associated with the 
accumulation of amyloid-beta (Aβ1-42) plaques and intra-neuronal tau tangles which are 
hypothesized to damage brain structures, impair brain metabolism, and result in the clinical 
manifestation of the disease [1,2]. Most individuals develop the sporadic form AD, which for the 
purpose of this review we operationally define as the form of AD with a late onset of clinical 
symptoms (i.e., >65 years old) and an etiology that is believed to not solely be determined by 
genetic influences [3]. A small percentage of AD cases, however, are caused by autosomal 
dominant mutations that typically result in an earlier onset of clinical symptoms (i.e. <65 years 
of age) [4], with age of symptom onset varying by mutation type [5–7]. Autosomal dominant 
mutations in genes such as the Presenilin1 (PSEN1) are nearly 100% penetrant and confer the 
development of AD with virtual certainty by midlife [8,9], providing a unique opportunity to 
study the biological and cognitive markers of AD across the preclinical and symptomatic stages 
of the disease. Beyond aiming to find treatments that benefit mutation-carriers, ADAD 
investigators work to elucidate the trans-diagnostic disease mechanisms between ADAD and the 
more common sporadic form of the disease. As ADAD kindreds provide a quasi-experimental 
framework to investigate AD mechanisms and treatments, to the degree which ADAD and 
sporadic AD are similar it is possible through ADAD research to generate testable research 
hypotheses for new ways to identify and treat individuals at risk for the sporadic form of AD.  
 
The largest identified single-mutation ADAD kindred in the world is a family of individuals with 
the E280A mutation in PSEN1 from Antioquia, Colombia [8–10]. Over 1,800 Colombian PSEN1 
E280A carriers and 4,000 non-carrier family members who trace their lineage back to a single-
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common ancestor with the mutation participate in research at the University of Antioquia and 
collaborating sites in the United States [11]. As research in this cohort progresses – including a 
five-year phase 2 clinical trial of the anti-amyloid agent Crenezumab involving 300 Colombian 
kindred members, 200 of whom are mutation carriers [12] – a review that unifies our 
understanding of the PSEN1 E280A literature is needed. 
 
Here, we synthesize all previous studies from the Colombian kindred, using a previously 
determined median estimated years until onset (EYO) of mild cognitive impairment (MCI) for 
this cohort (44 years) as a reference point to understand the progression of the cognitive and 
biological makers of the disease [10]; importantly, negative EYO indicates years before the 
median age of clinical onset of MCI, while positive EYO represents years after the median age 
of onset of MCI. We also provide directions for future research in this and other ADAD cohorts, 
including suggestions for generalizing ADAD findings to sporadic AD. 
 
Methods  
Thirty-four original reports (including published abstracts) on the cognitive and biological 
markers of PSEN1 E280A were identified, dating to 1997, which was the year of the first 
published research investigation in the cohort [13]. Studies from this cohort were defined using 
cohort characteristic criteria described in Lopera et al. (1997) and Acosta-Banea et al. (2011) 
[10,13]. All studies were found using Google Scholar, PubMed, and PsycInfo searches between 
November, 2017 and May, 2018. Search terms included: Presenilin1 E280A, Colombian kindred, 
autosomal dominant Alzheimer’s disease, familial Alzheimer’s disease. Articles found included 
works in both English and Spanish. All published reports on the biological and cognitive markers 
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of this cohort were included in this review. We break down our review by the type of 
measurement used in each study: clinical/cognitive, psychophysiological, functional 
neuroimaging, structural neuroimaging, and fluid and brain-based markers of AD pathology. 
 
As all the studies included in this review draw upon participants in the same cohort, identifying 
the exact number of unique participants is challenging. We can infer that some participants, such 
as those in the studies of child mutation carriers, were not included in other studies (i.e., studies 
of carriers with MCI or dementia due to AD, but otherwise the number of unique participants 
across all studies is difficult to identify. The median sample sizes of carriers and non-carriers 
across the cognitive studies were 40 and 30, respectively, including two large (n > 400 carriers) 
database-wide retrospective clinical and cognitive studies [10,14]. In comparison, for the 
psychophysiological studies the median sample size of carriers and non-carriers were 15 
individuals in each group. Across the functional imaging reports, there were median sample sizes 
of 21 carriers and 20 non-carriers. A median of 29 carriers and 23 non-carriers were included in 
the structural imaging studies. A median of 25 carriers and 21 non-carriers were used in the 
studies of the plasma, cerebral spinal fluid, and in vivo studies of this cohort. Table 1 provides a 
summary of the characteristics (number of published reports, EYO range, median sample size) 
and outstanding research questions for each cognitive and biological marker domain. For a 
synopsis statement on each published report from specific studies with the Colombian kindred, 
please see Supplementary Table A.  
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Results 
Cognitive Function 
The age of onset of dementia and rate of disease progression in this kindred was found to be 
variable [15], but a large, retrospective study of 449 mutation carriers identified a median age of 
onset of MCI of 44 years old, with a symptomatic disease course averaging 15 years thereafter 
[10]. Verbal memory deficits appeared in carriers between -9 to -14 EYO [10,16–20]. In 
addition, subjective memory complaint (SMC) scores based on study-partner report began to 
differ from non-carriers approximately -6 EYO and followed a linear function, correlating with 
hippocampal volume in these carriers in the preclinical stage of the disease [21]. Self-reported 
SMC was elevated in preclinical carriers relative to non-carriers, though a linear relationship 
with age was not found [21]. 
 
Poor performance on tests of attention, concentration, and semantic recognition was also 
observed in carriers approximately -5 EYO [16,17,22]. As mutation carriers progressed to 
dementia, memory and language problems worsened, and changes in personality, behavior and 
physical symptoms occurred [13]. Carriers of the PSEN1 E280A mutation with mild dementia 
(mean EYO from MCI = 5 years) performed worse than non-carriers on two thirds of tests from 
a battery of 43 neuropsychological variables [23].  
 
The visual short-term memory test by Parra and colleagues [24] also demonstrated potential as a 
possible marker of early cognitive decline in preclinical carriers [24–26]. Performance on the 
color-shape binding condition of this test reliably discriminated preclinical carriers from non-
carriers, even when other traditional neuropsychological tests could not, though a precise age at 
which this test begins to reveal deficits in carriers was not identified [24]. 
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Psychophysiological Measures 
Electroencephalogram (EEG) studies in the Colombian kindred, when considered together, 
provide evidence of a shift from hyperactivity to hypoactivity among frontal [27], perceptual 
[28,29], and memory-related [27,30–32] brain networks in carriers in the preclinical stage of the 
disease. Increased theta synchronization [33] and alterations in beta-band frequencies [34] in 
frontal regions of preclinical carriers occurred approximately -10 EYO [27,35], suggesting that 
abnormal cortical activity may occur in younger mutation carriers, despite similar cognitive 
performance to non-carriers. The right visuo-perceptual area, which showed greater activity in 
younger carriers, was conversely found to have decreased activity in carriers close to clinical 
onset [29]. In the context of other markers of AD, the change from EEG-measured cortical 
hyperactivity to hypoactivity in PSEN1 E280A carriers appeared to coincide with elevated levels 
of in vivo cortical Aβ1-42 in mutation carriers [36,37].  
 
Structural Imaging  
Structural magnetic resonance imaging (MRI) studies across ADAD mutations consistently 
suggest a pattern of decreased cortical thickness in the posterior parietal lobe of PSEN1 E280A 
mutation carriers before significant atrophy in other memory-related brain structures (e.g., the 
hippocampus and perihippocampus). The initial MRI study of kindred members showed that 
perihippocampal fissures and the distance between the unci of the temporal lobe distinguished 
symptomatic mutation carriers from cognitively unimpaired carriers and non-carrier family 
members, and that temporal lobe atrophy and ventricular enlargement (likely driven by the grade 
of atrophy) also correlated with disease severity [38]. Subsequent studies revealed decreased 
cortical thickness in the parietal lobe of young carriers (-18 to -26 EYO) [39] and broader 
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temporal and parietal reductions in thickness in carriers a decade before the median age of onset 
of MCI [40,41]. Complementing these studies of grey matter volume, one diffusion tensor 
imaging study measuring white matter integrity found significantly degenerated white matter 
only in carriers with dementia due to AD (mean EYO = 3 years) relative to non-carriers and 
preclinical carriers [26]. Decreased white matter integrity was observed most saliently in the 
mid-frontal lobe and the genu of the corpus callosum [26].  
 
Child PSEN1 E280A carriers (9-17 years old, -27 to -35 EYO) paradoxically showed greater 
grey matter volume compared to age-matched non-carriers in parietal and temporal areas [42], 
consistent with what has been observed in infant carriers of the E4 variant of the Apolipoprotein 
(ApoE4) who have greater grey matter in frontal areas relative to non-ApoeE4 carrier infants 
[43]. Evidence from the ApoE4 literature is mixed about whether greater frontal lobe matter in 
ApoE4-carrying infant relates to a potential executive-function-related compensatory 
neurodevelopmental process in these individuals at-risk for AD [44,45]. A study of child PSEN1 
E280A carriers is currently underway to attempt to similarly determine if Colombian kindred 
child mutation carriers who have greater grey matter in the parietal and temporal lobes show any 
cognitive deficits or strengths relative to non-carrier children. 
 
Functional Imaging    
The use of functional MRI (fMRI), hexamethylpropyleneamine oxime spectroscopy (SPECT), 
and fludeoxyglucose PET (FDG-PET) propelled the discovery of AD-related disruptions in the 
metabolism and activity of memory-related brain structures (e.g., the hippocampus) and in 
connectivity within networks associated with memory performance (e.g., the default mode 
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network, [DMN]) in PSEN1 E280A carriers. Prior studies have shown that, relative to non-
carriers, increased blood oxygenation level-dependent (BOLD) fMRI activation during the 
encoding phase of a face-name association task was evident in the right cingulate gyrus and the 
right anterior hippocampus in mutation carriers a mean of -11 EYO [46]. Younger carriers (-18 
to -26 EYO) also showed greater BOLD activation during encoding in the right hippocampus 
and parahippocampal gyrus on this task, as well as less deactivation in the precuneus and 
posterior cingulate cortex relative to matched non-carriers [39]. Child carriers (-27 to -35 EYO) 
similarly had less encoding-related deactivation of parietal regions and increased connectivity in 
the DMN between the posterior cingulate cortex and medial temporal lobe relative to non-
carriers during this task [42]. A scene-encoding BOLD fMRI task yielded similar encoding-
related hippocampal and parahippocampal gyri hyperactivation patterns as the face-name task, 
discriminating mutation carriers in the preclinical stage with a median of -10 EYO from non-
carriers [47]. 
 
In a SPECT study, preclinical mutation carriers in the decade before the estimated onset of MCI 
exhibited decreased cerebral perfusion in the posterior parietal lobe, the anterior frontal lobe, the 
posterior and anterior cingulate cortex, and throughout the hippocampal complex [48]. FDG-PET 
was used in a different study with adult carriers and revealed lower glucose metabolism in 
temporal and parietal regions (e.g., the posterior cingulate and precuneus) among carriers with 
approximately -18 EYO relative to non-carriers [49]. Carriers with dementia showed a similar 
pattern of decreased glucose metabolism as preclinical carriers [49], but had further decreased 
cerebral perfusion in the superior frontal cortex and posterior parietal lobe [48]. Findings of brain 
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hypometabolism among PSEN1 E280A carriers are generally consistent with the literature from 
individuals at risk for sporadic AD [50]. 
 
Plasma, CSF, and other in vivo markers of AD pathology  
Plasma, CSF, and in vivo PET studies provide evidence of AD pathogenesis in mutation carriers 
decades before the onset of clinical symptoms. Increased CSF Aβ1-42 distinguished young adult 
mutation carriers (-18- to -26 EYO) from non-carriers [39] while child mutation carriers (-27 to  
-35 EYO) showed elevated plasma Aβ1-42 and elevated ratios of plasma Aβ1-42 to Aβ1-40 when 
compared to non-carrier children [42]. Florbetapir PET imaging revealed Aβ1-42 aggregation in 
carriers with an average of -16 EYO, which increased steeply for almost 10 years until 
plateauing at -7 EYO [36]. Aβ1-42 aggregation was most evident in the anterior cingulate and 
precuneus [36]. Consistent with this initial study, a recent report using the Pittsburgh-compound-
B (PiB) tracer showed cortical Aβ1-42 aggregation beginning in carriers with an average of -15 
EYO [37]. Flortaucipir PET imaging of tau in the brain of carriers has shown progressive 
accumulation of tau in the entorhinal cortex and inferior temporal lobe an average of -6 EYO, 
and an estimated 10 years after the first evidence of cortical Aβ1-42 [37]. Tau aggregation was 
strongly related to performance on tests of verbal memory and global cognition, and could be 
seen in the junctions of the parietal, temporal, and occipital lobes, as well as in the posterior 
cingulate cortex and precuneus among carriers with MCI [37]. 
 
A single study extracted the sequential change points (and their 95% confidence intervals) for the 
CSF and brain biomarkers in carriers, revealing that the CSF Aβ1-42  was the earliest biomarker to 
show abnormality at -19 EYO, followed by PET markers of in vivo AD pathology, and finally 
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hippocampal volume at -5 EYO [51]. Further work with biomarkers has shown that baseline 
cortical Aβ1-42 and CSF phosphorylated-tau/Aβ1-42 ratios predicted cognitive decline over 2-3 
years among carriers with EYOs ranging from -24 to 0, whereas CSF Aβ1-42 and tau 
measurement levels (total tau and phosphorylated-tau [p-tau]) did not [52]. 
 
Discussion 
The near 100% penetrance of the PSEN1 E280A ADAD mutation has provided investigators 
with a unique framework to examine the course of the cognitive and biological markers of AD 
across the preclinical and symptomatic stages of the disease, something that cannot be readily 
done in sporadic AD populations without multi-decade longitudinal studies. Research in the 
Colombian kindred has included participants with a wide age range, including children, young 
cognitively unimpaired adults, and individuals with MCI and dementia due to AD. Figure 1 
draws from the cumulative studies across this wide age range and provides a cross-sectional 
synthesis of the findings from Colombian ADAD kindred based on the EYO of MCI for carriers 
of the PSEN1 E280A mutation. Ordering these findings based on EYO suggests that plasma and 
CSF Aβ1-42 are clinically abnormal early in the lives of PSEN1 E280A carriers, corresponding 
with early-life increases in connectivity (as seen on fMRI) within the DMN and hyperactivity (as 
measured by EEG) throughout the brain. Cortical Aβ1-42 deposition becomes evident a decade-
and-a-half later (~ -16 EYO), followed by decreased cerebral perfusion and glucose metabolism 
in brain regions impacted by cortical Aβ deposition, suggesting a potential connection between 
cortical Aβ1-42 and decreased parietal, frontal, and temporal metabolic activity in preclinical 
ADAD. Significantly decreased cortical thickness in parietal regions was also evident as carriers 
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approached the median age of onset of MCI, while child mutation carriers showed paradoxically 
greater grey matter than non-carriers in regions impacted by AD pathology.  
 
The differences seen between younger and older carriers of the PSEN1 E280A mutation suggest 
that the course of this ADAD mutation has a temporal order in which biofluid markers and 
electrophysiological measures may become abnormal early in the disease process. Structural 
imaging markers (e.g., grey matter volume, white matter integrity) provide evidence of 
degeneration much later in the preclinical stage of the disease close to the onset of clinical 
symptoms, although child mutation carriers show paradoxically greater cortical thickness in 
temporal and parietal regions. Figure 2 illustrates the course of structural MRI and fMRI 
signatures of PSEN1 E280A from childhood into adulthood, while Figure 3 shows the spatial 
pattern of cortical Aβ1-42 and temporal lobe tau deposition from the late preclinical stage of the 
disease to MCI. Synthesizing findings across PSEN1 E280A ADAD is essential to future 
research that will compare findings from this mutation to sporadic AD. Until longitudinal data 
are available for this cohort, using cross-sectional findings and EYO to model the hypothetical 
progression of disease is the best way to understand the earliest biological and cognitive events 
in ADAD at which pharmacological and non-pharmacological interventions may be most 
efficacious.   
 
Through the cumulative, synthesized findings of our review, we propose a hypothetical “tipping 
point” of hyper to hypo-activity in memory and visuo-perceptual regions in carriers in their mid-
thirties (~10 -EYO), which aligns with the mid-point between cortical Aβ deposition (median of 
-16 EYO) and regional tau deposition (median of -6 EYO) [36,37]. Significant debate persists, 
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however, about whether changes in cortical activation and functional activity are not 
compensatory, but reflective of poor brain maintenance. A prevailing counter-argument to the 
posterior-to-anterior compensatory shift in preclinical AD is that increased prefrontal activity in 
healthy older adults corresponds with decreased efficiency in neural networks [53]. While this 
question is still unresolved in the fields of sporadic AD and ageing, we note that the cognitively 
unimpaired PSEN1 E280A mutation carriers who participated in the studies of brain function 
were between 20-30 years younger than the earliest age at which one can be diagnosed with 
sporadic AD (65 years old) and were likely unaffected by ageing processes discrete from AD 
pathology. Studying cognitively unimpaired adult ADAD mutation carriers from this kindred 
mitigates many of the confounds of advancing age that are common in sporadic AD research.  
 
Several questions remain about how cortical Aβ1-42  relates to changes in cortical activation and 
functional connectivity in preclinical AD. For example, little is known about the deposition of 
Aβ1-42 or tau in the occipital lobe, so understanding changes in occipital lobe functioning in the 
context of AD pathologic change is an important area of future work in in the Colombian 
kindred. Grey and white matter degeneration and the aggregation of cortical Aβ1-42 and temporal 
lobe tau are also likely interrelated in ADAD; future work should further explore the relation 
between white matter integrity and AD pathologic change. A longitudinal study of members 
from the Colombian kindred that examines plasma, CSF, imaging, and cognitive function is 
currently underway with the hope of more definitively addressing these questions and elucidating 
the temporal relations between the cognitive and biological markers of preclinical ADAD. 
Similarly, studying EEG and in vivo brain pathology in the same sample could determine 
whether EEG hyper- or hypoactivity can reliably serve as a proxy for the aggregation of AD-
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related cortical Aβ1-42. The implications of such a study could facilitate the potential clinical and 
research use of EEG as a precursor assessment to more expensive (and less widely available) 
positron emission tomography (PET) imaging. Future research should also seek to integrate new 
behavioral measures and biomarker and imaging methods that will continue to expand our 
knowledge about the progression of AD, such as functional near-infrared spectroscopy (fNIRS) 
and PET imaging of other AD-related proteins. Understanding how health behaviors, like aerobic 
fitness and sleep hygiene, impact the course of AD is also a goal of ongoing research efforts in 
this cohort; two pilot studies currently underway to that explore how these health behaviors 
impact the biological and cognitive course of AD in PSEN1 E280A carriers.  
 
In addition to identifying the earliest imaging marker abnormalities of ADAD, cognitive and 
other clinical markers can play an important role as well. Studies from this cohort have suggested 
that short-term memory deficits in verbal [14] and visual memory [24–26] strongly discriminate 
preclinical PSEN1 E280A carriers from non-carriers, and are likely to be cost-effective screeners 
for preclinical AD. Continued detailed investigation of cognitive and behavioral markers 
sensitive to changes early in preclinical AD is warranted, with specific emphasis on exploring 
preclinical subclinical changes (i.e., close to the threshold but below cutoffs for statistical 
significance) in cognitive domains, such as executive function, that may underpin episodic 
memory problems in the early symptomatic stage of the disease.  
 
Our review also highlights the utility of examining PSEN1 E280A ADAD fluid and imaging 
progression in children younger than 8 years old, even younger than those investigated by Quiroz 
and colleagues (2015) [42]. Extending ADAD research with larger samples and longitudinal 
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follow up in younger children could provide the strongest evidence for neurodevelopmental 
changes in PSEN1 E280A ADAD.  If such changes were identified, this would underscore the 
importance of developing early-life interventions for these individuals. Extrapolating from the 
EYO of children carriers, ADAD-related abnormal memory network activity, as well as 
elevations of plasma Aβ1-42 and elevated ratios of plasma Aβ1-42 to Aβ1-42 may inform potential 
longitudinal or retrospective studies of sporadic AD that explore these abnormalities 
approximately 30 years before the onset of clinical symptoms.  
 
Like other narrative reviews, our approach is limited in that we pool research studies from the 
same kindred that vary in methodological design and participant age to extrapolate a 
hypothesized sequential change model across the disease. In addition, the normally inferable 
strength of replication by multiple studies is weakened in the set reviewed here, due to the high 
likelihood that some participants were measured in several studies. Nonetheless, given the robust 
characterization of this cohort and, in particular, the virtual guarantee that carriers of this 
mutation will develop clinical symptoms by mid-life, the data reviewed here can inform ongoing 
research on ADAD and sporadic AD. 
 
Findings to date from this PSEN1 E280A kindred generally support the prevailing models of AD 
pathogenesis and largely align with research from other ADAD groups, such as the Dominantly 
Inherited Alzheimer’s Network (DIAN), which suggest that CSF markers of amyloid-beta 
change earliest in the disease process, followed by decline in brain metabolism, and lastly by 
atrophy in memory-related brain structures (e.g., the hippocampus) which is closer to the age of 
onset of cognitive decline [54]. Reports from the Colombian kindred also generally align with 
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studies of sporadic AD [55,56]. The most precise understanding of disease-course will, however, 
come from longitudinal studies. We are collecting such data now, and these data as well as those 
from DIAN other ADAD research groups will facilitate comparisons with longitudinal studies of 
sporadic AD (e.g., the Harvard Aging Brain Study, the Alzheimer’s Disease Neuroimaging 
Initiative, and the Australian Imaging, Biomarker & Lifestyle study). Studies that compare data 
from ADAD kindreds and sporadic AD groups should ensure that, when feasible, parallel 
protocols for imaging, biomarker collection, and cognitive testing are followed. While the 
clinical and cognitive course of ADAD appears to follow a similar course to that in sporadic AD, 
initial studies comparing the two etiologically distinct forms of AD should prioritize testing 
whether specific biological and cognitive markers in the preclinical stage of ADAD occur at 
similar points before clinical onset and predict risk for clinical progression in sporadic AD 
populations. Studying ADAD kindreds, like the Colombian PSEN1 E280A cohort, is an 
approach that affords an understanding of the cognitive and biological course of AD separate 
from age-related processes and co-morbidities (e.g., stroke and white matter hyperintensities). As 
carriers of the PSEN1 E280A mutation are virtually guaranteed to develop MCI and dementia 
due to AD by their mid-to-late 40s, the effects age-related processes on the cognitive and 
biological changes seen in ADAD are believed to be low to non-existent.  
 
Over the next decade, collaborations between ADAD and sporadic AD research groups may 
substantially advance our understanding of the generalizability of ADAD findings to the more 
common sporadic form of the disease, while also highlighting those changes that are specific to 
early onset forms of the disease. As we approach the new frontier of AD research that aims to 
find an effective prevention or treatment for AD by 2025 [57], longitudinal research and 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
REVIEW OF MARKERS OF PSEN1 E280A ADAD 
 
 20 
comparisons between PSEN1 E280A ADAD and sporadic AD cohorts will be essential to 
advancing our understanding of when the AD pathophysiological process begins, how to most 
accurately identify individuals at risk for AD in late life early on, where in the disease process 
intervention will be most efficacious, and what the most effective and stage-specific 
interventions might be. 
 
Conclusions 
Significant abnormalities in plasma, CSF, and brain-based AD pathology, as well as differences 
in brain structure and function (despite preserved cognition) are evident in carriers of the PSEN1 
E280A mutation as early as three-and-a-half decades before the median age of onset of AD-
related cognitive decline. Findings from the Colombian kindred have laid the groundwork for 
better understanding the prognostic value of fluid and in vivo imaging markers of ADAD.  
However, continued integration and comprehensive evaluation of the biological and cognitive, 
and other clinical markers of ADAD will inform the search for the earliest sensitive and specific 
markers of the disease and direct the development of interventions for the preclinical stage of 
AD. Generalizing findings from the Colombian kindred to sporadic AD will be the next wave of 
research in this kindred, carrying significant implications for clinical trials, research, and 
treatment of the disease.  
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FIGURE LEGEND 
Figure 1. Hypothetical Model of Progression of Biological Markers of PSEN1 E280A 
Autosomal Dominant Alzheimer’s Disease Relative to Earliest Known Signal of Cognitive 
Decline. A synthesis of the Colombian kindred biological marker literature is presented as a 
function of the estimated years until the median age of onset of mild cognitive impairment in this 
cohort. The hypothetical trajectory of the biological markers of ADAD in this cohort are 
displayed relative to the earliest known signs of cognitive decline at a median age of -12 EYO 
(dashed line; Acosta-Baenta et al., 2011). Figure 1a examines biological markers of brain 
function, while Figure 1b charts biological markers of brain structure and AD-related pathology.  
 
Note: fMRI = EEG = electroencephalogram; FDG-PET = fludeoxyglucose positron emission 
tomograph; SPECT = single-photon emission computerized tomography; FMRI = functional 
magnetic resonance imaging; DMN = default mode network; MRI = structural magnetic 
resonance imaging; WM = white matter; DTI = diffusion tensor imaging; Aβ = amyloid-beta; 
PET = positron emission tomography; MTL = medial temporal lobe; CSF = cerebral spinal fluid.  
 
Figure 2. A) Child mutation carriers (-36 to -27 EYO), relative to non-carrier children, show 
paradoxically greater cortical thickness in the parietal and temporal lobe, as indicated by the 
color blue; cognitively unimpaired adult mutation carriers, however, exhibit decreased cortical 
thickness relative to non-carriers in the posterior parietal lobe, as indicated by the colors red and 
yellow. B) Relative to non-carrier children, child PSEN1 mutation carriers show decreased 
deactivation of the posterior parietal lobe and increased hippocampal activation during memory 
encoding (Quiroz et al., 2015); cognitively unimpaired adult PSEN1 mutation carriers also 
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exhibit decreased deactivation of the posterior parietal lobe and increased hippocampal 
activation during memory encoding (Reiman et al., 2012). 
 
Figure 3. Comparison of the spatial patterns of tau deposition in PSEN1 E280A mutation 
carriers. Amyloid-positive PSEN1 mutation carriers display greater tau levels in the entorhinal 
cortex and regions of the inferior temporal lobe; deposition is believed to begin around -6 EYO 
(Quiroz et al., 2018). 
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Table 1: Summary of Characteristics of Published Cognitive and Biological Marker Reports of PSEN1 E280A ADAD 
Modality of study 
Number of 
published 
reports* 
EYO range of 
mutation 
carriers 
Median sample 
size of mutation 
carriers (and non-
carriers) 
Questions that need further investigation 
Cognitive tests 13 
-26 EYO to 
dementia due 
to ADAD 
40(30)** 
Are there cognitive markers that occur earlier than 
verbal memory impairment that extant measures are 
not sensitive enough to detect? What cognitive 
differences distinguish child mutation carriers from 
non-carrier children? 
Psychophysiological (EEG) 7 
-18 EYO to 
dementia due 
to ADAD 
15(15) 
Can EEG serve as proxy for preclinical aggregation 
of cortical amyloid-beta? What does EEG activation 
look like in child carriers of the mutation?  
Brain function (fMRI; 
SPECT; FDG-PET) 
6 
-35 EYO to 
dementia due 
to ADAD 
21(20) 
Are there SPECT and FDG-PET differences seen in 
younger carriers (e.g., -25 EYO) than those in two 
published reports? 
Brain structure (MRI; DTI) 6 
-35 EYO to 
dementia due 
to ADAD 
29(23) 
At what age does the paradoxically greater cortical 
thickness in child carriers convert to cortical 
thinning? Do specific pathological processes drive 
this change? 
Biomarkers (Plasma, CSF, 
amyloid-beta and tau PET) 
7 
-35 EYO to 
dementia due 
to ADAD 
25(21) 
How do changes in blood and CSF markers of AD 
pathology relate to preclinical differences in cortical 
activation and functional connectivity? 
 
Note: 
*Some reports share overlapping modalities (e.g., brain function and biomarkers). 
**The median sample size of the studies of cognitive testing is driven by two large (n > 400) retrospective studies.  
Abbreviations: EYO = estimated years until onset of mild cognitive impairment; EEG = electroencephalogram; fMRI = functional magnetic 
resonance imaging; SPECT = single-photon emission computed tomography; FDG-PET = fludeoxyglucose positron emission tomography; 
MRI = magnetic resonance imaging; DTI = diffusion tensor imaging; CSF = cerebral spinal fluid; PET = position emission tomography  
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